

# Family Medicine and *Patient-Centered* Asthma Care

Presented by the  
California Academy of Family Physicians



# Faculty: Hobart Lee, MD



Hobart Lee, MD  
Assistant Professor,  
Dept. of Family  
Medicine and  
Program Director  
Family Medicine  
Residency, Loma  
Linda University,  
Loma Linda, CA

Disclosures: Jeffrey Luther, MD, Program Director, Memorial Family Medicine Residency Program in Long Beach, CA also served on the Content Development Team for this program.

Drs. Lee and Luther declare that neither they nor members of their immediate family have financial relationships with the manufacturers of goods or services discussed, or corporate supporters of this event.

Drs. Lee and Luther are not discussing or presenting information that is related to off-label or investigational use of any therapy, product, or device.

CAFP staff involved in the planning of this activity declare no financial relationships.



# Disclosure and Industry Support

- The CAFP Committee on Continuing Professional Development is responsible for management and resolution of conflict for any individual who may have influence on content, who have served as faculty, or who may produce CME/CPD content for the CAFP.
- It is the policy of CAFP to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities.
- This activity is supported by unrestricted educational grants from Boehringer Ingelheim and Sunovion.



# Learning Objectives

- Apply latest evidence-based guidelines in the diagnosis and management of asthma.
- Use simplified, efficient processes to interpret spirometry results.
- Name the six key messages from the GIP report.
- Name several sources to identify appropriate inhalers and help patients understand importance of accurate technique when using inhalers.
- Demonstrate effective and culturally competent communication skills to improve patient engagement and adherence to asthma management plans.




# Definition: Asthma

- Chronic disease of the airways that may cause
  - Wheezing
  - Breathlessness
  - Chest tightness
  - Nighttime or early morning coughing
- Episodes are usually associated with widespread, but variable, airflow obstruction within the lung that is often reversible either spontaneously or with treatment



# Prevalence

## Current Asthma Prevalence Percents by Age, Sex, and Race, United States, 2010



Source: National Health Interview Survey, National Center for Health Statistics, Centers for Disease Control and Prevention

CSJ296594-4



# Burden: Every day in America

- 44,000 people have an asthma attack.
- 36,000 kids miss school due to asthma.
- 27,000 adults miss work due to asthma.
- 4,700 people visit the emergency room due to asthma.
- 1,200 people are admitted to the hospital due to asthma.
- 9 people die from asthma.



# Population Disparities

- Current asthma prevalence is higher among:
  - Children than adults
  - Boys than girls
  - Women than men
- Asthma morbidity and mortality is higher among:
  - African Americans



# Risk Factors

- Genetic
- Obesity
- Sex

PLUS:

- Environmental
  - Allergens
  - Infections
  - Smoke
  - Diet
  - Air Pollution



# Guidelines

- NHLBI: National Asthma Education and Prevention Program (NAEPP)
  - Expert Panel Report 3 (417 pages)
  - Guidelines Implementation Panel (GIP)
- GOLD: Global Initiative for Chronic Obstructive Lung Disease
- GINA: Global Initiative for Asthma
  - Collaborative of NHLBI and WHO
- ICSI: Institute for Clinical Systems Improvement
  - Focuses on Triple Aim



# What is GIP?

- Guidelines Implementation Panel Report for Expert Panel Report 3
- Recommendations and strategies to implement EPR-3
- **Six** key messages



# GIP Messages

## 1. Use Inhaled Corticosteroids

Inhaled corticosteroids are the most effective medications for long-term management of persistent asthma.

## 2. Use Asthma Action Plan

All people who have asthma should receive a written asthma action plan to guide their self-management efforts.

## 3. Asthma Severity

All patients should have an initial severity assessment based on measures of current impairment and future risk to determine type and level of initial therapy needed.



# GIP Messages

## 4. Asthma Control

Patients should review the level of control with their PCP to guide decisions.

## 5. Schedule Follow-up Visits

Needed to assess asthma control and to modify treatment if needed.

## 6. Allergen and Irritant Exposure Control


Review each patient's sensitivity to allergens and irritants and provide a multipronged strategy to reduce exposure.



# Making the Diagnosis

- Medical History
- Physical Exam
- Tests for Dx and Monitoring
  - Spirometry
  - Peak expiratory flow





# Meet Samantha

Samantha is a 19-year-old college sophomore.

She's had asthma since childhood but hasn't seen a physician in years.

She describes symptoms 3-4 times/week and she awakens with asthma ~once/week.

Her symptoms respond to a short-acting  $\beta$ -agonist.



Samantha also tells you she:

Smoked for awhile in high school, but quit after starting college

Has an extensive history of seasonal allergies

Plays midfield for college soccer team, but rarely has symptoms with exercise



# Spirometry: Testing Lung Function



# Spirometry

- Normal:  $0.7 < FEV1/FVC < 0.8$
  - Older patients: 0.65-0.70 may be normal
  - Younger patients:  $> 0.70$  may be abnormal
- 
- Use lower limit of normal (LLN) to help distinguish in young and old patients





You perform office spirometry. Her FEV<sub>1</sub> is 60% of predicted and her FEV<sub>1</sub>/FVC ratio is 66%; these are fully reversible after short-acting bronchodilator.

What is Samantha's diagnosis by spirometry?

- 0% 1. Normal
- 0% 2. Obstructive disease
- 0% 3. Restrictive disease
- 0% 4. Mixed obstructive/restrictive disease

# Spirometry patterns

DIAGNOSIS	Spirometry values
Normal	FEV <sub>1</sub> and FVC > 80% FEV <sub>1</sub> /FVC ratio > 0.7
Obstructive	FEV <sub>1</sub> < 80% FVC normal or reduced (less than FEV <sub>1</sub> ) FEV <sub>1</sub> /FVC ratio < 0.7
Restrictive	FEV <sub>1</sub> normal or mildly reduced FVC below 80% predicted FEV <sub>1</sub> /FVC ratio normal (> 0.7)
Mixed	FEV1 reduced FVC reduced FEV1/FVC reduced



# Severity

- Intensity of untreated disease
- Determined by
  - Current impairment
  - Future risk
- Guides decisions for initiating therapy





Samantha has daytime symptoms 3-4x/week and nighttime symptoms 1x/week. Her FEV<sub>1</sub> is 66% of predicted. She went to urgent care once this past year for asthma symptoms.

What is Samantha's asthma severity?

- 0% 1. Intermittent
- 0% 2. Persistent - mild
- 0% 3. Persistent - moderate
- 0% 4. Persistent - severe

7

Countdown

# Classifying Impairment

## Classification of asthma severity $\geq 12$ years of age\*

Components of severity	Intermittent	Persistent-mild	Persistent-moderate	Persistent-severe
Symptoms	$\leq 2$ days per week	$> 2$ days per week, not daily	Daily	Throughout the day
Nighttime awakenings	$\leq 2$ times per month	3 to 4 times per month	$> Once$ per week, but not nightly	Often 7 times per week
Short-acting beta agonist use for symptom control (not for prevention of exercise-induced bronchospasm)	$\leq 2$ days per week	2 days/wk, but no more than daily	Daily	Several times per day
Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited
Lung function	Normal FEV <sub>1</sub> between exacerbations; FEV <sub>1</sub> $>80\%$ of predicted; FEV <sub>1</sub> /FVC normal	FEV <sub>1</sub> $\geq 80\%$ of predicted; FEV <sub>1</sub> /FVC normal	FEV <sub>1</sub> 60-80% of predicted; FEV <sub>1</sub> /FVC reduced 5%	FEV <sub>1</sub> $< 60\%$ of predicted; FEV <sub>1</sub> /FVC reduced $>5\%$

# Classifying Risk

	Intermittent	Persistent Mild	Persistent Mod	Persistent Severe
<b>Exacerbations requiring systemic corticosteroids</b>	0 – 1/year	≥ 2/year	≥ 2/year	≥ 2/year

Consider severity and interval since last exacerbation; frequency and severity may fluctuate over time for patients in any severity category; relative annual risk of exacerbations may be related to FEV<sub>1</sub>




# Treatment

- Short-acting  $\beta$ -agonists
- Inhaled corticosteroids
- Third-line agents:
  - Long-acting  $\beta$ -agonists
  - Leukotriene antagonists
  - Other



# Environmental Allergens

- Ask about allergens, including indoor inhalants (e.g. cigarette smoking)
- Use skin or in vitro testing to determine sensitivities and correlate with patient history
- Assess for seasonal allergies



# Address Allergens and Triggers

- Reduce allergen exposure with multifaceted, comprehensive approach
- Avoid smoke/pollution, med/food sensitivities
- Consider allergen immunotherapy
- Treat co-morbid conditions





# Which of the following instructions for inhaler use is not correct?


- 0% 1. Shake the inhaler before using
- 0% 2. Breathe out and breath in quickly as you press down on the inhaler
- 0% 3. Hold your breath and count to 10 slowly
- 0% 4. For short-acting rescue meds, wait about 1 minute between puffs
- 0% 5. For steroid inhalers, rinse and spit your mouth after each use

# A Word About Inhaler Use

- Technique is critical to medication delivery
- Physician should demonstrate and observe inhaler use
- Education materials:
  - Handout
  - Video



# Demonstrate inhaler technique



# Ongoing Management

- Symptom control
- Activity levels / exercise
- Pulmonary function
- Prevent asthma exacerbations
- Avoid adverse effects from asthma medications
- Prevent asthma mortality



# Assess and Monitor Control

- Current impairment
  - Frequency/intensity of symptoms
  - Functional limitations experienced
- Future risk
  - Likelihood of exacerbations
  - Decline in lung function
  - Risk of adverse medication effects



# EPR-3: Classification of Control: Current Impairment

Symptom awareness: Same as when assessing severity

Questionnaires: Asthma Therapy Assessment  
Questionnaire  
Asthma Control Questionnaire  
Asthma Control Test

Peak flow monitoring: Symptom monitoring as effective  
as peak flow monitoring in assessing  
asthma control

Control assessment also takes into account risk



# Action Plans

**Written** asthma action plan is important for self-management education.

Strongest benefit for moderate/severe asthma (stage 3 or higher), history of severe exacerbations, or poorly controlled asthma

What Should  
be Included  
in an Action Plan?

- Daily Management
- How to recognize and handle worsening asthma



# Follow-up

- 2-6 week after starting/changing meds
- 1-6 months if stable
- Focus on communication and teaching patients did not lengthen visit times (e.g. reviewing written asthma action plan)



## Recommendations for All Subsequent Visits

### Focus on:

- Expectations of visit
- Asthma control
- Patients' goals of treatment
- Medications
- Quality of life

Ask relevant questions from previous visits and also ask:

“How have you tried to control things that make your asthma worse?”

“Please show me how you use your inhaled medication.”

### Teach in simple language:

- Review and reinforce all:
  - Educational messages
  - Environmental control strategies at home, work, or school
  - Medications
  - Self-assessment of asthma control, using symptoms and/or peak flow as a guide


### Teach or review and demonstrate:

- Inhaler/spacer or VHC technique.
- Peak flow monitoring technique, if appropriate.
- Use of written asthma action plan. Review and adjust as needed.
- Confirm that patient knows what to do if asthma gets worse.

Sources: Adapted from Guevara et al. 2003; Janson et al. 2003; Powell and Gibson 2003; Wilson et al. 1993.



# Back to Samantha: Putting her at the Center of Care



# Patient Non-Adherence

## World Health Organization

Only 50% of patients take medication as prescribed.

Non-adherence affects Americans of all ages, both genders and across socioeconomic levels

## NCPIE, August 2007 \*

Lack of medication adherence estimated at \$177 billion annually:

- ✓ Unnecessary disease progression;
- ✓ Disease complications;
- ✓ Reduced functional abilities;
- ✓ Lower quality of life;
- ✓ Premature death

*\* National Council on Patient Information and Education, August 2007*

© 2013/California Academy of Family Physicians



# Patient-Doctor Partnership

- Communication is key!
- We are asking patients to:
  - Identify and control triggers
  - Take meds based on symptom (or peak-flow) based algorithm
  - Identify and self-treat exacerbations
  - Appropriately communicate with family physicians for additional help



# Partnership and Shared-decision making

- Determine patient's personal goals and treatment preferences
- Share general asthma goals
- Agree on shared goals of treatment
- Provide a written asthma action plan



# Educate, educate, educate

- “No symptoms, no asthma” belief
- Latino ethnocultural belief that asthma is a “cold” illness
- Patient’s reading level strongest predictor of asthma knowledge and proper MDI use



# Social Media and Asthma



# Patient resources



- <http://familydoctor.org/familydoctor/en/diseases-conditions/asthma.html>
- <http://www.ginasthma.org/Patients>
- <http://www.patient.co.uk/health/asthma>



# Key Take Home Points

- Initial assessment focuses on asthma severity
- Regular follow-up needs to address control
  - Both severity and control relate to degree of impairment and future risk
- Inhaled corticosteroids are most effective for long-term management of persistent asthma
- Control of allergen/irritant exposure contributes to control
- Patient engagement and shared decision-making are key
  - Asthma action plan facilitates self-management





Thank You!  
Questions



# Resources

- NHLBI Guidelines for the Diagnosis and Treatment of Asthma (EPR-3)
  - <http://www.nhlbi.nih.gov/guidelines/asthma/index.htm>
- Global Initiative for Asthma (GINA)
  - Pocket Guide for Asthma Management & Prevention. Available from:
    - <http://www.ginasthma.org/documents/1>
  - Global Strategy for Asthma Management and Prevention, 2012. Available from:
    - <http://www.ginasthma.org>



# Action Plans

- Public Health Institute Regional Asthma Management and Prevention (RAMP) Initiative
  - [http://www.nhlbi.nih.gov/heart/public/lung/asthma/asthma\\_actplan.pdf](http://www.nhlbi.nih.gov/heart/public/lung/asthma/asthma_actplan.pdf)
- California Asthma Public Health Initiative, CA Dept of Health Services
  - [http://fhop.ucsf.edu/fhop/docs/pdf/prods/interventPlan/ip\\_AsthmaActionPlanpdf](http://fhop.ucsf.edu/fhop/docs/pdf/prods/interventPlan/ip_AsthmaActionPlanpdf)

